ALLO - Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

• Allogene Therapeutics ( NASDAQ: ALLO ) has i nitiated the phase 2 ALPHA2 trial of ALLO-501A , an allogeneic chimeric antigen receptor T cell (AlloCAR T) therapy, for relapsed/refractory large B-cell lymphoma.
• The stock is up 12% in after-hours trading.
• The biotech said the trial is the first phase 2 study of a allogeneic CAR T treatment.
• The single-arm trial will involve a single dose of ALLO-501A at 120 million CAR+ cells and will enroll ~100 patients with at least two prior lines of therapy and who have not received prior anti-CD19 therapy. The primary endpoint is objective response rate.
• Allogene ( ALLO ) is also in the process of beginning the phase 2 EXPAND trial for ALLO-647, an anti-CD52 monoclonal antibody, which would be used with ALLO-501A and other AlloCAR T therapies to improve clinical outcomes.
• Check out why Seeking Alpha contributor Terry Chrisomalis is very bullish on Allogene's ( ALLO ) prospects.

For further details see: